Investors Center

Cannapowder Inc. (OTCMARKETS: CAPD) is developing revolutionary nanometric cannabis powders to enable cannabis users, whether for recreational or medicinal purposes, to more-efficiently nteract with the Endocannabinoid mechanism.
Nanometric powder – is an innovative drug delivery mechanism which is highly efficient and offers opportunities that the current cannabis delivery systems fail to provide at all or do so inefficiently.

Stock Quote

Ticker:

Last:

Change:

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Investors Tools

Stock Chart
SEC Filings

The FDA Approval Process and government Regulation

We believe the powders we are developing will facilitate the production of cannabinoid-based drugs for the treatment of patients suffering from certain diseases, disorders and medical conditions. However, at present, because of U.S. Food and Drug Administration (“FDA”) and Drug Enforcement Administration (“DEA”) restrictions, most companies involved in research and development of cannabinoid therapeutic applications, especially in the United States, currently use synthetics.

Furthermore, we believe that demand for cannabinoid-derived drugs will continue to increase driven by favorable changes in legislation and growing public approval, among other factors, although we have no control over these factors and there can be no assurance that these trends will continue, or that the U.S. federal government will change its position regarding the legalization of medical or recreation cannabis. Nevertheless, we believe that the U.S.

Within the European Community (EU), medical cannabis program regulatory frameworks currently exist in countries, including the Netherlands, Italy, Germany, Finland, Norway, Ukraine, Estonia, Switzerland and the Czech Republic. It is also anticipated that there will be positive policy changes in many member countries of the European Union regarding the medical use of cannabis and cannabinoid-derived drugs, although there can be no assurance that a positive regulatory environment will continue. In addition, medical cannabis has been decriminalized in Russia, Mexico, Columbia, Uruguay, Paraguay and Colombia.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This website presentation by CannaPowder, Inc. (the “Company” or “CannaPowder”) contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology.

These forward-looking statements include,
but are not limited to:

our ability to manage our product development working with our collaboration partners in Israel

our ability to generate market acceptance for our products in development

our ability to attract and retain key officers and employees, including key personnel at our wholly-owned Israeli subsidiary, Canna Powder Ltd

our ability to raise capital and obtain financing on acceptable terms

our ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have

our ability to keep pace with a changing industry and its rapidly evolving technology demands and regulatory environment

our ability to protect and enforce intellectual property rights

These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing regulatory environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus.

We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the U.S., we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or other investments or strategic transactions we may engage in.